Empirical Finance LLC Buys 252 Shares of Illumina, Inc. (NASDAQ:ILMN)

Empirical Finance LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 17.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,733 shares of the life sciences company’s stock after acquiring an additional 252 shares during the period. Empirical Finance LLC’s holdings in Illumina were worth $820,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. BDO Wealth Advisors LLC increased its stake in shares of Illumina by 90.5% in the first quarter. BDO Wealth Advisors LLC now owns 80 shares of the life sciences company’s stock valued at $31,000 after buying an additional 38 shares during the period. Evoke Wealth LLC raised its stake in shares of Illumina by 165.6% during the first quarter. Evoke Wealth LLC now owns 85 shares of the life sciences company’s stock valued at $33,000 after acquiring an additional 53 shares during the last quarter. Eagle Bay Advisors LLC acquired a new position in shares of Illumina during the second quarter worth $35,000. Tsfg LLC increased its holdings in Illumina by 1,580.0% in the second quarter. Tsfg LLC now owns 84 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 79 shares during the period. Finally, Meridian Wealth Partners LLC bought a new position in Illumina during the 1st quarter worth $41,000. Institutional investors own 88.56% of the company’s stock.

In related news, SVP Susan H. Tousi sold 300 shares of Illumina stock in a transaction on Monday, June 28th. The stock was sold at an average price of $478.95, for a total transaction of $143,685.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Charles Dadswell sold 314 shares of the firm’s stock in a transaction on Monday, August 23rd. The shares were sold at an average price of $489.10, for a total value of $153,577.40. The disclosure for this sale can be found here. Insiders have sold a total of 3,881 shares of company stock worth $1,873,334 over the last ninety days. Insiders own 0.23% of the company’s stock.

NASDAQ ILMN opened at $448.85 on Wednesday. The company has a market cap of $65.85 billion, a P/E ratio of 85.99, a PEG ratio of 2.24 and a beta of 0.91. The company has a fifty day simple moving average of $482.60 and a 200 day simple moving average of $438.65. The company has a current ratio of 6.08, a quick ratio of 5.64 and a debt-to-equity ratio of 0.32. Illumina, Inc. has a 12-month low of $260.42 and a 12-month high of $555.77.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, August 5th. The life sciences company reported $1.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.36 by $0.51. Illumina had a net margin of 19.36% and a return on equity of 18.12%. The business had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter last year, the firm earned $0.62 EPS. Sell-side analysts predict that Illumina, Inc. will post 6.48 EPS for the current year.

Several equities research analysts have recently weighed in on the company. Robert W. Baird reissued a “hold” rating on shares of Illumina in a research note on Sunday, August 22nd. Barclays upped their price objective on shares of Illumina from $355.00 to $365.00 and gave the company an “underweight” rating in a research note on Friday, August 6th. SVB Leerink lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $425.00 target price on the stock. in a report on Thursday, August 19th. Canaccord Genuity upped their price target on shares of Illumina from $515.00 to $555.00 and gave the company a “buy” rating in a research report on Monday, August 9th. Finally, Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $504.00 price objective for the company in a research report on Wednesday, June 30th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $392.06.

About Illumina

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

See Also: Do equity income investments outperform growth and income investments?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.